FSD Pharma Inc. HUGE
Set alert
At close · Aug 14
52-week range unavailable
- Open
- 0.095
- Prev close
- 0.0899
- Mkt cap
- 66.67K
- Vol
- 22.02M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.087
- High
- 0.1042
- Forward P/E
- -0.75
- Beta
- 0.00
- Short ratio
- 0.11
- Inst. own
- 2.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 8.13
- 200-d avg
- 36.69
- 1y target
- 2.60
Key statistics
- Market cap
- 66.67K
- Enterprise value
- 287.16K
- Trailing P/E
- 0.00
- Forward P/E
- -0.75
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.01
- EPS (TTM)
- -16.25
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.05M
- Total cash
- 3.33M
- Total debt
- 625.20K
- Return on equity
- -63.89%
- Shares outstanding
- 708.61K
- Short % of float
- 0.44%
- 50-day average
- 8.13
- 200-day average
- 36.69
Analyst view
Consensus: buy
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 14, 2024 | Jun 1, 2024 | -0.06 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.05 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Jul 20, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
About FSD Pharma Inc.
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- Canada
- Website
- fsdpharma.com
News
- Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
- Court Sides with Quantum BioPharma in Dispute with Dr. Bokhari, Legal Battle Continues Over $2.8M Award
- Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
- Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation
- Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
- FSD Pharma Announces Share Consolidation and Name Change
- FSD Pharma Is Up 216% Today. What Is Going On With HUGE Stock?
- FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
- 24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
Your note
Sign in to keep a note on HUGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bokhari (Raza) | 10% Security Holder of Issuer | Redemption, retraction, cancelation, repurchase | Mar 28, 2022 | 5,527 |
| Carroll (Donal) | Director of Issuer | Acquisition or disposition in the public market | Sep 26, 2022 | 263,444 |
| Coyle (Nathan Patrick) | Senior Officer of Issuer | Acquisition or disposition in the public market | Jun 9, 2022 | 2,500 |
| Durkacz (Anthony John) | 10% Security Holder of Issuer | Acquisition or disposition in the public market | Apr 24, 2022 | 273,597 |
| FSD Pharma, Inc. | Issuer | Redemption, retraction, cancelation, repurchase | Sep 25, 2022 | 219,400 |
| Kotra (Lakshmi) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition or disposition in the public market | Dec 6, 2021 | 298,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 0.63% | 249,305 | 286.70K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.26% | 102,600 | 117.99K | Jun 29, 2023 |
| Susquehanna International Group, LLP | 0.15% | 57,465 | 66.08K | Jun 29, 2023 |
| Janney Montgomery Scott LLC | 0.04% | 15,000 | 17.25K | Jun 29, 2023 |
| Two Sigma Securities, LLC | 0.03% | 10,165 | 11.69K | Jun 29, 2023 |
| Royal Bank of Canada | 0.01% | 2,176 | 2.50K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.60% | 235,637 | 285.26K | Sep 29, 2023 |